Zoetis Q1 2025 revenue $2.2B (+9% organic), adj EPS $1.48; affirms 6-8% organic growth for FY

Zoetis Inc.

2025-Q1 EPS reported $1.41 revenue$2,220,000,000

Revenue $2.2B (+1% reported, +9% organic operational); net income $631M, diluted EPS $1.41.
Adjusted net income $662M, adj diluted EPS $1.48; +6% organic operational growth YoY.
U.S. segment revenue $1.2B (+6% organic); International $1.0B (+11% organic on operational basis).
FY25 guidance: revenue $9.425-9.575B (6-8% organic); adj diluted EPS $6.20-6.30, reflecting FX and tariffs.
Simparica Trio gains U.S. flea tapeworm label; avian influenza vaccine conditional license in U.S./Canada.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.